Since there are currently no known XRCC1 inhibitors, to further explore a possible role of XRCC1 in the sensitivity to β-lap in PDA cells, we knocked down over 90% of the expression of XRCC1 mRNA in the MiaPaCa2 cells and BxPC3 cells through pLVX-shXRCC1 (Fig. 2C&D) and then evaluated β-lap-induced lethality by relative survival. Here, XRCC1 is linked to Patent ductus arteriosus.